Abstract
Traditional contact tracing for COVID-19 tests the direct contacts of those who test positive even if the contacts do not show any symptom. But, by the time an infected individual is tested, the infection starting from the person may have infected a chain of individuals. Hence, why should the testing stop at direct contacts, and not test secondary, tertiary contacts or even contacts further down? One deterrent in testing long chains of individuals right away may be that it substantially increases the testing load, or does it? We investigate the costs and benefits of such multi-hop contact tracing for different number of hops. Considering a large number of contact topologies, spanning synthetic networks of divergent characteristics and those constructed from recorded interactions, we show that the cost-benefit tradeoff can be characterized in terms of a single measurable attribute, the initial epidemic growth rate. Once this growth rate crosses a threshold, multi-hop contact tracing substantially reduces the outbreak size compared to traditional contact tracing. Multi-hop even incurs a lower cost compared to the traditional contact tracing for a large range of values of the growth rate. The cost-benefit tradeoffs and the choice of the number of hops can be classified into three phases, with sharp transitions between them, depending on the value of the growth rate. The need for choosing a larger number of hops becomes greater as the growth rate increases or the environment becomes less conducive toward containing the disease.
Author summary The COVID-19 pandemic has wrecked havoc on lives and livelihoods worldwide. Other epidemics may well emerge in future and one needs a preparedness to prevent their growth into another pandemic. During the early stages of a new epidemic, or even a mutated version of an earlier epidemic, pharmaceutical interventions may not be available but contact tracing and timely quarantine are among the few available control measures. We show that 1) traditional contact tracing may not successfully contain the outbreak depending on the rate of growth of the epidemic, but 2) the cost-benefit tradeoffs may be substantially enhanced through the deployment of a natural multi-hop generalization which tests contact chains starting from those who test positive.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NIH AI-132971 and NSF career award 2047482
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work does not need any approval of the IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* jungyeol{at}seas.upenn.edu
Data Availability
Relevant data are within the manuscript and Supporting Information. Contact networks generated during this study are available from the repository https://github.com/jungyeol-kim/contact-tracing.
